Free Newsletter
Merck chalks up another Vioxx victory
A Florida jury ruled for Merck in yet another Vioxx case, bringing the drug maker's record to 11-5 in trials related to the drug. The newest case involved a former professional soccer player, Refik Kozic, who had a heart attack in 2001 at the age of 50. The jury decided that Vioxx didn't cause Kozic's heart attack.
Merck, of course, pulled Vioxx from the market in 2004 because of increased risk of heart attack and stroke. Some 45,000 product liability cases are pending.
- check out Merck's release
Related Articles:
NY double-teams Merck in Vioxx lawsuit. Report
Merck takes tough stance on Vioxx. Report
Vioxx defense dealt a blow by new study results. Report
Up to 100,000 Vioxx claims expected. Report
Merck faces long road in Vioxx battle. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: